Zacks Research Issues Negative Forecast for CPRX Earnings

Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) – Stock analysts at Zacks Research cut their Q4 2024 earnings estimates for Catalyst Pharmaceuticals in a research note issued to investors on Wednesday, November 27th. Zacks Research analyst A. Chakraborty now anticipates that the biopharmaceutical company will post earnings of $0.46 per share for the quarter, down from their prior estimate of $0.48. The consensus estimate for Catalyst Pharmaceuticals’ current full-year earnings is $1.88 per share. Zacks Research also issued estimates for Catalyst Pharmaceuticals’ Q3 2025 earnings at $0.54 EPS, Q4 2025 earnings at $0.57 EPS, Q2 2026 earnings at $0.58 EPS and FY2026 earnings at $2.36 EPS.

CPRX has been the topic of a number of other reports. Stephens began coverage on Catalyst Pharmaceuticals in a research report on Monday, November 18th. They set an “overweight” rating and a $35.00 target price on the stock. HC Wainwright reissued a “buy” rating and issued a $30.00 price objective on shares of Catalyst Pharmaceuticals in a research note on Friday, November 8th. StockNews.com upgraded shares of Catalyst Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Friday, August 9th. Truist Financial upped their price target on shares of Catalyst Pharmaceuticals from $30.00 to $36.00 and gave the company a “buy” rating in a report on Monday, November 11th. Finally, Citigroup raised their price objective on shares of Catalyst Pharmaceuticals from $27.00 to $31.00 and gave the stock a “buy” rating in a research note on Friday, August 9th. Seven equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, Catalyst Pharmaceuticals presently has an average rating of “Buy” and a consensus target price of $31.14.

Catalyst Pharmaceuticals Price Performance

Shares of NASDAQ:CPRX opened at $22.07 on Monday. The firm has a market capitalization of $2.63 billion, a price-to-earnings ratio of 18.70, a price-to-earnings-growth ratio of 3.40 and a beta of 0.75. The business’s 50 day simple moving average is $21.26 and its 200-day simple moving average is $18.79. Catalyst Pharmaceuticals has a 12 month low of $13.00 and a 12 month high of $24.27.

Insider Buying and Selling at Catalyst Pharmaceuticals

In related news, Director Molly Harper sold 17,500 shares of the firm’s stock in a transaction that occurred on Wednesday, November 27th. The shares were sold at an average price of $22.00, for a total value of $385,000.00. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, insider Gary Ingenito sold 12,000 shares of the company’s stock in a transaction that occurred on Wednesday, November 27th. The stock was sold at an average price of $22.72, for a total transaction of $272,640.00. Following the transaction, the insider now directly owns 51,391 shares of the company’s stock, valued at $1,167,603.52. This trade represents a 18.93 % decrease in their position. The disclosure for this sale can be found here. 11.00% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Several large investors have recently made changes to their positions in the company. Pacer Advisors Inc. increased its stake in Catalyst Pharmaceuticals by 130,918.8% during the second quarter. Pacer Advisors Inc. now owns 2,967,575 shares of the biopharmaceutical company’s stock worth $45,968,000 after acquiring an additional 2,965,310 shares during the last quarter. Renaissance Technologies LLC grew its holdings in shares of Catalyst Pharmaceuticals by 15.2% during the 2nd quarter. Renaissance Technologies LLC now owns 2,175,727 shares of the biopharmaceutical company’s stock worth $33,702,000 after purchasing an additional 287,300 shares during the period. Jane Street Group LLC increased its position in Catalyst Pharmaceuticals by 245.4% during the 3rd quarter. Jane Street Group LLC now owns 401,908 shares of the biopharmaceutical company’s stock worth $7,990,000 after purchasing an additional 285,564 shares in the last quarter. Integral Health Asset Management LLC purchased a new position in Catalyst Pharmaceuticals in the second quarter valued at approximately $4,260,000. Finally, Dimensional Fund Advisors LP lifted its position in Catalyst Pharmaceuticals by 9.6% during the second quarter. Dimensional Fund Advisors LP now owns 3,000,756 shares of the biopharmaceutical company’s stock valued at $46,479,000 after buying an additional 263,099 shares in the last quarter. 79.22% of the stock is owned by hedge funds and other institutional investors.

About Catalyst Pharmaceuticals

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.